Not an actual patient. | †See Terms and Conditions

Another Day, Another Itch You Shouldn’t Scratch

Life’s an itch. Good thing there’s Eurax.1

Commercially-insured, eligible patients may pay as little as:

$0†

Search icon Find an in-network pharmacy

Not an actual patient. | †See Terms and Conditions

  • Non-antihistamine1
  • fragrance-free1
  • Non-steroidal1

Eurax can provide fast-acting, ongoing relief to help keep your itch at bay.1,2

  • NON-STEROIDAL.1
  • NON-ANTIHISTAMINE.1
  • FRAGRANCE-FREE.1
Icon indicating pruritus can be caused by various medical conditions

Pruritus can be caused by a wide variety of medical conditions, such as atopic dermatitis, psoriasis, allergies and systemic conditions.3

Icon representing disruption of the itch-scratch cycle

Eurax disrupts the itch / scratch cycle for histamine- and non-histamine-mediated itch.1,4,5

Icon representing ongoing itch relief

Eurax provides general itch relief that’s non-steroidal and non-histamine.1,2

Itching to try a different treatment option?

In an observational study of 124 patients suffering from a variety of skin conditions, but with itch as a main concern:2

94% of patients who applied Eurax® (crotamiton, 10%) reported complete or considerable itch relief.2

2.4% of patients experienced mild skin irritation.2

Most patients reported itch relief lasting 6-10 hours, and some patients experienced almost instant relief.2

STUDY DESIGN

124 patients with a variety of dermatologic conditions, but with pruritus as a chief complaint, were treated symptomatically with 10% crotamiton in a washable ointment base. They were advised to use the ointment as frequently as needed to control itching, and to note the time when the pruritis disappeared and reappeared. Out of 124 patients, 82 (66.2%) self-reported complete relief, 34 (27.4%) self-reported considerable relief and 8 (6.4%) self-reported little or no relief. In 3 cases (2.4%), patients had a local reaction, which was a mild erythema, and proved to be caused by the washable ointment base. This study was published in The Journal of Investigative Dermatology in 1949.2

Not an actual patient.

How Eurax Works

Help keep the itch at bay

Itch happens when signals pass through special channels (TRPV4) in your skin’s nerve cells, telling your brain that you feel itchy.4,5

Diagram showing how crotamiton reduces TRPV4 channel activity to decrease itch signals

Crotamiton, the active ingredient in Eurax, is thought to help limit how often these channels open, reducing the number of itch signals reaching the brain, so you feel less itchy.4,5

Simply less scratching

Eurax provides simple, fast-acting itch relief that’s non-steroidal and non-antihistamine.1,2

Step 1
Icon indicating Eurax can be reapplied up to 4 times per day

Gently massage into itchy areas until Eurax is completely absorbed.1

Step 2
Eurax crotamiton cream 10% tube

Repeat as necessary, up to 4 times per day.1

Applying Eurax.1

  • Massage Eurax gently into the itchy areas on your skin until it is completely absorbed.
  • Repeat as necessary, up to 4 times per day.
  • Can be used over widespread itchy areas.
  • Do not apply to the eyes or mouth or to acutely inflamed, raw or weeping skin.
  • In a few patients, adverse reactions such as itch, rash, and allergic sensitivity were reported.
  • Available as a 60 g tube.
Not an actual patient.

Scratch the itch to save through the Journey Total Access Program.

Commercially-insured, eligible patients may pay as little as:

$0†

†TERMS & CONDITIONS
This program offer is only good with a prescription of Eurax® and is valid for Eurax® (NDC 69489-311-60). This program offer is not valid for prescriptions reimbursed by Medicare, Medicaid, federal or state programs (including any state prescription drug programs). This program offer is valid only in the United States and cannot be redeemed at government subsidized pharmacies. Not valid with any other offer. Maximum reimbursement limits apply. Void where prohibited.

Search icon Find an in-network pharmacy

Ask your dermatologist if Eurax could tame your uncontrollable itch.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: For eradication of scabies (Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

SUMMARY OF RISK INFORMATION FOR EURAX CREAM

CONTRAINDICATIONS: Do not apply EURAX topically to patients who develop sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

WARNINGS: Discontinue treatment with this product if severe irritation or sensitization develops, and institute appropriate therapy.

PRECAUTIONS: Do not apply EURAX in the eyes or mouth because it may cause irritation. Do not apply on acutely inflamed skin or raw or weeping surfaces until the acute inflammation has subsided.

It is not known whether EURAX can cause fetal harm when applied topically to a pregnant woman or can affect reproduction capacity. EURAX should be given to a pregnant woman only if clearly needed.

PRECAUTIONS: Safety and effectiveness in pediatric patients have not been established.

Clinical studies with EURAX did not include sufficient numbers of subjects aged 65 years and older to determine whether they
respond differently than younger subjects.

ADVERSE REACTIONS: Primary irritation reactions, such as dermatitis, pruritus, and rash, and allergic sensitivity reactions have been reported in a few patients.

This preparation is not for ophthalmic, oral, or intravaginal use.

To report SUSPECTED ADVERSE REACTIONS, contact Journey Medical Corporation at 1-855-531-1859 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For topical use only. Please see Full Prescribing Information.

REFERENCES

  1. Eurax® (crotamiton, USP) Cream (10% w/w) [prescribing information]. Scottsdale, AZ: Journey Medical Corporation. May 2026.
  2. Couperus M. The use of N-ethyl-ocrotonotoluidide in the treatment of scabies and various pruritic dermatoses. J Invest Dermatol. 1949;13(1):35-42.
  3. NHS Inform. Itching. Available from https://www.nhsinform.scot/illnesses-and-conditions/skin-hair-and-nails/itching. Accessed Jan 12, 2022.
  4. Kittaka H, et al. Transient receptor potential vanilloid 4 (TRPV4) channel as a target of crotamiton and its bimodal effects. Pflugers Arch. 2017;469(10):1313-1323.
  5. Kim S, et al. Facilitation of TRPV4 by TRPV1 is required for itch transmission in some sensory neuron populations. SciSignal. 2016;9(437):ra71.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: For eradication of scabies (Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

SUMMARY OF RISK INFORMATION FOR EURAX CREAM

CONTRAINDICATIONS: Do not apply EURAX topically to patients who develop sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

WARNINGS: Discontinue treatment with this product if severe irritation or sensitization develops, and institute appropriate therapy.

PRECAUTIONS: Do not apply EURAX in the eyes or mouth because it may cause irritation. Do not apply on acutely inflamed skin or raw or weeping surfaces until the acute inflammation has subsided.

It is not known whether EURAX can cause fetal harm when applied topically to a pregnant woman or can affect reproduction capacity. EURAX should be given to a pregnant woman only if clearly needed.

PRECAUTIONS: Safety and effectiveness in pediatric patients have not been established.

Clinical studies with EURAX did not include sufficient numbers of subjects aged 65 years and older to determine whether they
respond differently than younger subjects.

ADVERSE REACTIONS: Primary irritation reactions, such as dermatitis, pruritus, and rash, and allergic sensitivity reactions have been reported in a few patients.

This preparation is not for ophthalmic, oral, or intravaginal use.

To report SUSPECTED ADVERSE REACTIONS, contact Journey Medical Corporation at 1-855-531-1859 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For topical use only. Please see Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: For eradication of scabies (Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

SUMMARY OF RISK INFORMATION FOR EURAX CREAM

CONTRAINDICATIONS: Do not apply EURAX topically to patients who develop sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

WARNINGS: Discontinue treatment with this product if severe irritation or sensitization develops, and institute appropriate therapy.

PRECAUTIONS: Do not apply EURAX in the eyes or mouth because it may cause irritation. Do not apply on acutely inflamed skin or raw or weeping surfaces until the acute inflammation has subsided.

It is not known whether EURAX can cause fetal harm when applied topically to a pregnant woman or can affect reproduction capacity. EURAX should be given to a pregnant woman only if clearly needed.

PRECAUTIONS: Safety and effectiveness in pediatric patients have not been established.

Clinical studies with EURAX did not include sufficient numbers of subjects aged 65 years and older to determine whether they
respond differently than younger subjects.

ADVERSE REACTIONS: Primary irritation reactions, such as dermatitis, pruritus, and rash, and allergic sensitivity reactions have been reported in a few patients.

This preparation is not for ophthalmic, oral, or intravaginal use.

To report SUSPECTED ADVERSE REACTIONS, contact Journey Medical Corporation at 1-855-531-1859 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For topical use only. Please see Full Prescribing Information.